当前位置:首页 - 行情中心 - 泓博医药(301230) - 财务分析 - 利润表

泓博医药

(301230)

  

流通市值:16.71亿  总市值:30.30亿
流通股本:5937.17万   总股本:1.08亿

利润表

报告期2023-09-302023-06-302023-03-312022-12-31
公司类型通用通用通用通用
一、营业总收入367,212,523.37237,655,059.97121,392,447.24478,883,784.02
营业收入367,212,523.37237,655,059.97121,392,447.24478,883,784.02
二、营业总成本319,387,817.06200,328,331.16104,504,260.72409,404,459.84
营业成本240,119,484.14149,336,941.3477,917,655.65302,301,235.06
税金及附加915,160.49555,131.18312,473.121,661,733.28
销售费用8,888,306.95,522,548.532,563,164.878,118,909.95
管理费用43,886,738.7928,819,361.4513,311,726.4972,047,018.45
研发费用28,719,012.4519,284,150.4610,163,571.9232,652,599.49
财务费用-3,140,885.71-3,189,801.8235,668.67-7,377,036.39
其中:利息费用2,940,547.932,030,341.211,045,393.664,792,709.47
其中:利息收入4,163,429.143,518,749.043,058,391.182,883,818.4
加:公允价值变动收益2,357,183.57-2,986,215.19901,397.8-99,354.73
加:投资收益726,006.943,015,155.93461,082.24603,323.91
资产处置收益5,799.543,020.493,020.49-
资产减值损失(新)-2,407,037.97-2,009,778.3-1,365,671.84-2,163,660.74
信用减值损失(新)-151,336.611,005,917.866,893.06252,660.06
其他收益1,139,587.97416,428.87413,168.874,772,986
营业利润平衡项目0000
四、营业利润49,494,909.7536,771,258.4117,368,077.1472,845,278.68
加:营业外收入6,750.226,750.026,150.02205,669.67
减:营业外支出502,018.64279,580.57137,019.6129,425.36
利润总额平衡项目0000
五、利润总额48,999,641.3336,498,427.8617,237,207.5672,921,522.99
减:所得税费用3,065,623.613,610,235.11,961,411.215,745,640.54
六、净利润45,934,017.7232,888,192.7615,275,796.3567,175,882.45
持续经营净利润45,934,017.7232,888,192.7615,275,796.3567,175,882.45
归属于母公司股东的净利润45,934,017.7232,888,192.7615,275,796.3567,175,882.45
(一)基本每股收益0.430.310.21.1
(二)稀释每股收益0.430.310.21.1
八、其他综合收益69,910.2682,460.8682,460.86-30,320.53
归属于母公司股东的其他综合收益69,910.2682,460.8682,460.86-30,320.53
九、综合收益总额46,003,927.9832,970,653.6215,358,257.2167,145,561.92
归属于母公司股东的综合收益总额46,003,927.9832,970,653.6215,358,257.2167,145,561.92
公告日期2023-10-262023-08-292023-04-262023-04-22
审计意见(境内)标准无保留意见
TOP↑